# Relaxin Therapy for Atrial Fibrillation

Study · id `cardio:ct-nct07359872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07359872](<https://clinicaltrials.gov/study/NCT07359872>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07359872

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 208 participants.

## Technical summary

Registry record NCT07359872. Randomized; quadruple masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 208 participants (planned count; ClinicalTrials.gov record NCT07359872, source copy `cardio:ctgov-nct07359872-2026-01-22`, retrieved 2026-10-26)
- Planned start: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07359872, source copy `cardio:ctgov-nct07359872-2026-01-22`, retrieved 2026-10-26)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07359872, source copy `cardio:ctgov-nct07359872-2026-01-22`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07359872, source copy `cardio:ctgov-nct07359872-2026-01-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07359872-2026-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Relaxin Therapy for Atrial Fibrillation
- Acronym: Relax-in-AF
- Condition: Atrial Fibrillation (AF)
- Condition: Arrhythmia
- Condition: Oxidative Stress
- Condition: Stroke
- Condition: Major Cardiovascular Event
- Condition: Heart Failure
- Condition: Catheter Ablation
- Condition: Ablation of Atrial Fibrillation
- Intervention (Drug): Relaxin
- Intervention (Drug): Placebo
- Lead sponsor: Deeptankar DeMazumder
- Lead sponsor class: FED
- Collaborator: Relaxera Pharmaceuticals
- Collaborator class: UNKNOWN
- Collaborator: McGowan Institute for Regenerative Medicine, University of Pittsburgh
- Collaborator class: UNKNOWN
- Collaborator: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: df61e07c4c6448f75b6dbf0532db81f23a617984668bf267274b4d28fbce99da
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
